FDC Limited has announced that its ophthalmic formulations facility in Waluj, Aurangabad, has received a renewed Good Manufacturing Practice (GMP) certificate from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (UK MHRA). The approval allows the Indian pharmaceutical manufacturer to maintain its regulatory clearance to export ophthalmic products to the UK market and other regions that recognize UK GMP standards.
The company said the renewed GMP status follows a recent inspection conducted remotely by the UK MHRA between 6 September and 9 September 2021. The certificate confirms that the manufacturing site continues to meet the UK regulator’s quality, safety, and operational standards for sterile ophthalmic medicines.
How does UK MHRA GMP certification strengthen FDC Limited’s export market position in ophthalmic drugs?
The UK MHRA GMP certification is regarded as one of the most stringent manufacturing compliance benchmarks for pharmaceutical companies. For FDC Limited, the continued recognition from the UK regulator enables the firm to maintain its product supply to regulated markets, particularly the United Kingdom, and to other countries that accept UK MHRA certification as part of their import requirements.
The ophthalmic facility in Waluj produces a range of sterile eye care products, including anti-infectives, anti-allergy formulations, lubricating drops, and glaucoma treatments. The UK MHRA certificate effectively validates that the site’s production, quality control, and packaging processes meet the high standards necessary for export to advanced markets.
Industry analysts note that ophthalmic drugs require especially rigorous quality controls due to their sterile nature and the sensitive application route. Regulatory approvals from agencies like the UK MHRA signal to buyers, distributors, and healthcare systems that the manufacturing site is capable of producing consistent, safe, and effective medicines.
What was the scope and process of the remote GMP inspection by the UK MHRA?
According to FDC Limited, the September 2021 inspection was conducted entirely in a remote format, in line with global regulatory adaptations during the COVID-19 pandemic. This remote inspection model uses secure video conferencing, electronic documentation sharing, and virtual site walkthroughs to assess compliance.
Inspectors from the UK MHRA reviewed manufacturing records, quality management system documentation, sterilization process validation data, and training logs. They also examined the plant’s adherence to aseptic processing protocols, raw material testing, finished product stability studies, and deviation handling procedures.
The successful completion of the remote audit without critical observations allowed the UK MHRA to issue the renewed GMP certificate, extending the site’s status as an approved exporter to the UK.
What is the significance of Waluj as a pharmaceutical manufacturing hub in India?
Waluj, located in the Aurangabad district of Maharashtra, has grown into a strategic industrial hub for multiple sectors, including pharmaceuticals. The area’s connectivity, availability of skilled workforce, and established supply chain infrastructure have attracted numerous pharma manufacturers to set up large-scale production units.
For FDC Limited, the Waluj facility plays a key role in its specialty manufacturing portfolio. In addition to ophthalmics, the company’s network of plants produces formulations across therapeutic areas including anti-infectives, cardiovascular drugs, antidiabetics, nutraceuticals, and oral rehydration salts (ORS). The continued compliance of the Waluj site with international GMP standards enhances the company’s ability to service regulated markets while meeting domestic demand.
How does UK MHRA compliance impact FDC Limited’s global regulatory standing?
A GMP certification from the UK MHRA is recognized by several international regulatory bodies due to the UK’s participation in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and mutual recognition agreements. This can reduce duplication of inspections for FDC Limited when seeking approvals in other regulated markets, such as the European Union, Australia, and parts of the Middle East.
Moreover, the certification helps streamline product registration processes in countries that rely on UK MHRA assessment reports as part of their own review. This regulatory efficiency can shorten time-to-market for new ophthalmic launches and support the company’s long-term international growth strategy.
What is the current global demand outlook for ophthalmic pharmaceuticals?
The global ophthalmic pharmaceuticals market has been experiencing steady growth, driven by rising prevalence of eye disorders such as dry eye disease, glaucoma, cataracts, and age-related macular degeneration. Increased awareness of preventive eye care, an aging population, and higher diagnosis rates are also contributing to market expansion.
Sterile ophthalmic products are subject to some of the most stringent manufacturing controls in the pharmaceutical sector. Companies with validated GMP-compliant facilities in emerging markets like India are well-positioned to supply both branded and generic products to cost-sensitive healthcare systems globally.
For FDC Limited, the UK MHRA certification for its Waluj ophthalmic facility reinforces its ability to compete in this growing segment by ensuring uninterrupted access to key export markets.
What does this mean for FDC Limited’s long-term manufacturing and export strategy?
FDC Limited’s management has consistently emphasized the importance of maintaining global regulatory certifications across its manufacturing network. By securing renewed UK MHRA compliance for the Waluj site, the company protects its existing export business and strengthens its credibility with multinational partners and contract manufacturing clients.
In addition, the certification supports FDC Limited’s positioning as a reliable supplier in tender-driven markets, where proof of compliance with recognized GMP standards can be a decisive factor in securing contracts.
The company’s continued investment in quality systems, workforce training, and technology upgrades at Waluj is aligned with its strategy to grow its footprint in ophthalmics and other sterile dosage forms.
What is the industry sentiment and analyst perspective on FDC Limited’s renewed UK MHRA GMP certification?
Pharmaceutical market watchers generally view regulatory re-certifications from stringent agencies as positive indicators of operational robustness. Maintaining such approvals, especially in sterile manufacturing, reflects the company’s ability to sustain high standards over time rather than just achieving compliance for a one-time inspection.
While specific analyst reports from November 2021 were not cited in FDC Limited’s announcement, generic industry sentiment suggests that companies with consistent UK MHRA compliance are better equipped to weather competitive pressures in both regulated and semi-regulated markets.
For investors, customers, and partners, the Waluj facility’s renewed GMP certificate reduces perceived operational and regulatory risks, enhancing FDC Limited’s standing in the ophthalmic segment.
How does this certification position FDC Limited for future growth in ophthalmics?
FDC Limited’s renewed GMP certification from the UK MHRA for its Waluj ophthalmic facility marks a continuation of its compliance track record in sterile manufacturing. By successfully completing a remote inspection, the Indian pharmaceutical manufacturer demonstrates adaptability to evolving regulatory processes while maintaining stringent production standards.
The certification not only secures market access to the United Kingdom but also reinforces the company’s eligibility for other export destinations that accept UK MHRA benchmarks. With global demand for ophthalmic drugs on the rise, FDC Limited’s ability to produce high-quality, regulatory-approved products from its Aurangabad facility places it in a competitive position to capture new opportunities in the segment.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
